Nymirum
Yang is a biotech entrepreneur experienced in early-stage technology commercialization and building value-driving partnerships across companies, academic centers and government organizations. He previously co-founded MicroQuin (oncology) and served as its COO and CBO, as well as Oxalo Therapeutics (renal) and served as its COO.
Yang received his MBA from the University of Chicago Booth School of Business and his BA in Business Economics from UCLA. While at the University of Chicago, he worked with the entrepreneurship center to spin-out STEM research.
Nymirum
Nymirum exploits the dynamics and atomic-scale structure of RNA to guide novel small molecule drug discovery.